The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-escalation study evaluating the effects of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with select relapsed or refractory hematologic malignancies.
Alexander M. Lesokhin
Research Funding - Bristol-Myers Squibb
Martin Gutierrez
No relevant relationships to disclose
Ahmad Sami Halwani
No relevant relationships to disclose
Stephen Maxted Ansell
Research Funding - Bristol-Myers Squibb
Philippe Armand
Consultant or Advisory Role - Merck
Ivan Borrello
No relevant relationships to disclose
Zdenka E Segota
No relevant relationships to disclose
Adam D. Cohen
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Millennium; Onyx
Moshe Talpaz
Consultant or Advisory Role - ARIAD
Honoraria - ARIAD
Research Funding - ARIAD
Deepika Cattry
No relevant relationships to disclose
Tracy Turner
Employment or Leadership Position - Bristol-Myers Squibb
Maria Mezes
Employment or Leadership Position - Bristol-Myers Squibb
Christina Hartman
Employment or Leadership Position - Bristol-Myers Squibb
Ashok Kumar Gupta
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Su Young Kim
Employment or Leadership Position - Bristol-Myers Squibb
Jon M. Wigginton
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
John Timmerman
Research Funding - Bristol-Myers Squibb